Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.12
NYSE:EBS's Cash to Debt is ranked lower than
78% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NYSE:EBS: 1.12 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:EBS' s Cash to Debt Range Over the Past 10 Years
Min: 0.52  Med: 2.08 Max: N/A
Current: 1.12
Equity to Asset 0.59
NYSE:EBS's Equity to Asset is ranked lower than
60% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NYSE:EBS: 0.59 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:EBS' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.68 Max: 0.81
Current: 0.59
0.33
0.81
Interest Coverage 7.50
NYSE:EBS's Interest Coverage is ranked lower than
88% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NYSE:EBS: 7.50 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:EBS' s Interest Coverage Range Over the Past 10 Years
Min: 7.05  Med: 2815.62 Max: N/A
Current: 7.5
F-Score: 4
Z-Score: 3.22
M-Score: -2.61
WACC vs ROIC
10.84%
5.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.13
NYSE:EBS's Operating margin (%) is ranked higher than
79% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NYSE:EBS: 9.13 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:EBS' s Operating margin (%) Range Over the Past 10 Years
Min: 9.13  Med: 16.93 Max: 25.7
Current: 9.13
9.13
25.7
Net-margin (%) 8.70
NYSE:EBS's Net-margin (%) is ranked higher than
80% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NYSE:EBS: 8.70 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:EBS' s Net-margin (%) Range Over the Past 10 Years
Min: 8.16  Med: 11.81 Max: 18.07
Current: 8.7
8.16
18.07
ROE (%) 7.57
NYSE:EBS's ROE (%) is ranked higher than
83% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NYSE:EBS: 7.57 )
Ranked among companies with meaningful ROE (%) only.
NYSE:EBS' s ROE (%) Range Over the Past 10 Years
Min: 5.5  Med: 10.76 Max: 23
Current: 7.57
5.5
23
ROA (%) 4.74
NYSE:EBS's ROA (%) is ranked higher than
85% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NYSE:EBS: 4.74 )
Ranked among companies with meaningful ROA (%) only.
NYSE:EBS' s ROA (%) Range Over the Past 10 Years
Min: 4.23  Med: 6.85 Max: 13.46
Current: 4.74
4.23
13.46
ROC (Joel Greenblatt) (%) 11.84
NYSE:EBS's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NYSE:EBS: 11.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:EBS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 11.5  Med: 24.3 Max: 61.78
Current: 11.84
11.5
61.78
Revenue Growth (3Y)(%) 12.60
NYSE:EBS's Revenue Growth (3Y)(%) is ranked higher than
63% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NYSE:EBS: 12.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:EBS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -1.1  Med: 10.9 Max: 31.3
Current: 12.6
-1.1
31.3
EBITDA Growth (3Y)(%) 32.80
NYSE:EBS's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NYSE:EBS: 32.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:EBS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -2.1 Max: 32.8
Current: 32.8
0
32.8
EPS Growth (3Y)(%) 29.40
NYSE:EBS's EPS Growth (3Y)(%) is ranked higher than
83% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NYSE:EBS: 29.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:EBS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -26.7  Med: 2.1 Max: 61.7
Current: 29.4
-26.7
61.7
» NYSE:EBS's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

EBS Guru Trades in Q4 2015

Joel Greenblatt 446,867 sh (New)
Jim Simons 951,611 sh (+22.91%)
Ken Fisher 457,742 sh (-0.19%)
Paul Tudor Jones 26,796 sh (-17.21%)
» More
Q1 2016

EBS Guru Trades in Q1 2016

Jim Simons 1,112,811 sh (+16.94%)
Ken Fisher 457,742 sh (unchged)
Joel Greenblatt 443,728 sh (-0.70%)
Paul Tudor Jones 24,632 sh (-8.08%)
» More
Q2 2016

EBS Guru Trades in Q2 2016

Jim Simons 1,274,211 sh (+14.50%)
Joel Greenblatt 465,311 sh (+4.86%)
Ken Fisher 467,770 sh (+2.19%)
Paul Tudor Jones 16,200 sh (-34.23%)
» More
Q3 2016

EBS Guru Trades in Q3 2016

Paul Tudor Jones Sold Out
Ken Fisher 453,870 sh (-2.97%)
Jim Simons 1,178,111 sh (-7.54%)
Joel Greenblatt 242,516 sh (-47.88%)
» More
» Details

Insider Trades

Latest Guru Trades with EBS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CHRS, OTCPK:MPSYY, NAS:DERM, OTCPK:SXMDF, NAS:FOLD, NAS:AMAG, NAS:ALDR, NAS:RGEN, NAS:INVA, NAS:XNCR, NAS:ARRY, NAS:PTLA, OTCPK:PFSCF, NAS:BGNE, NAS:FWP, NAS:AIMT, NAS:OPHT, NYSE:AXON, NAS:BPMC, NAS:CORT » details
Traded in other countries:ER4.Germany,
Emergent BioSolutions Inc is a specialty biopharmaceutical company operating in two divisions: Biodefense and Biosciences. Its products include BioThrax, BAT, Anthrasil, VIGIV, RSDL, NuThrax, PreviThrax and GC-072.

Emergent BioSolutions Inc was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. The Company is a biopharmaceutical company, which is focused on the development, manufacture and commercialization of vaccine and immune-related therapeutic that assist the body's immune system to prevent or treat disease. It develops vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism and biowarfare and infectious diseases that have resulted in unmet or underserved public health needs. The Company manufactures and markets BioThrax(r), also referred to as anthrax vaccine adsorbed, the only vaccine approved by the U.S. Food and Drug Administration, or FDA, for the prevention of anthrax infection. BioThrax is approved for pre-exposure prevention of anthrax infection by all routes of exposure, including inhalation. The Company operates in two business segments, biodefense and biosciences. Its biodefense segment focuses on vaccines and therapeutics for use against biological agents that are potential weapons of bioterrorism or biowarfare. Its product candidates in this segment are focused on two specific biological agents: anthrax and botulinum. Within its anthrax product portfolio, the Company manufactures and markets BioThrax(r) (Anthrax Vaccine Adsorbed), the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax infection. In addition to BioThrax, the Company is developing a recombinant protective antigen anthrax, or rPA, vaccine an advanced BioThrax vaccine, an anthrax immune globulin therapeutic and a recombinant anthrax monoclonal antibody therapeutic. Within its botulinum product portfolio, it is developing a recombinant botulinum vaccine. The Company's Biosciences division is a specialty pharmaceutical business focused on therapeutics and vaccines in hematology/oncology, transplantation and infectious disease. The Company's products and any product or product candidate that it acquires or successfully develop and commercialize is likely to compete with currently marketed products, such as vaccines, antibody therapies, antibiotics and other product candidates that are in development for the same indications. Specifically, the competition for its products and product candidates includes BioThrax, RSDL, BAT, AIGIV, VIGIV and PreviThrax and NuThrax. Accordingly, it is subject to federal, state, local and foreign laws and regulations governing the use, manufacture, distribution, storage, handling, disposal and recordkeeping of these materials.

Ratios

vs
industry
vs
history
P/E(ttm) 32.35
EBS's P/E(ttm) is ranked higher than
52% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. EBS: 32.35 )
Ranked among companies with meaningful P/E(ttm) only.
EBS' s P/E(ttm) Range Over the Past 10 Years
Min: 5.26  Med: 20.89 Max: 67.2
Current: 32.35
5.26
67.2
Forward P/E 13.81
EBS's Forward P/E is ranked higher than
65% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. EBS: 13.81 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 57.69
EBS's PE(NRI) is ranked lower than
70% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. EBS: 57.69 )
Ranked among companies with meaningful PE(NRI) only.
EBS' s PE(NRI) Range Over the Past 10 Years
Min: 5.26  Med: 21.25 Max: 67.2
Current: 57.69
5.26
67.2
Price/Owner Earnings (ttm) 367.52
EBS's Price/Owner Earnings (ttm) is ranked lower than
92% of the 142 Companies
in the Global Biotechnology industry.

( Industry Median: 28.19 vs. EBS: 367.52 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
EBS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.9  Med: 35.52 Max: 1470
Current: 367.52
5.9
1470
P/B 2.45
EBS's P/B is ranked higher than
73% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. EBS: 2.45 )
Ranked among companies with meaningful P/B only.
EBS' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 1.79 Max: 3.61
Current: 2.45
0.8
3.61
P/S 2.78
EBS's P/S is ranked higher than
84% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. EBS: 2.78 )
Ranked among companies with meaningful P/S only.
EBS' s P/S Range Over the Past 10 Years
Min: 0.71  Med: 2.17 Max: 4.07
Current: 2.78
0.71
4.07
POCF 24.15
EBS's POCF is ranked higher than
50% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. EBS: 24.15 )
Ranked among companies with meaningful POCF only.
EBS' s POCF Range Over the Past 10 Years
Min: 2.45  Med: 13.07 Max: 102.3
Current: 24.15
2.45
102.3
EV-to-EBIT 25.68
EBS's EV-to-EBIT is ranked lower than
53% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. EBS: 25.68 )
Ranked among companies with meaningful EV-to-EBIT only.
EBS' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.7  Med: 13.6 Max: 38.3
Current: 25.68
1.7
38.3
EV-to-EBITDA 14.59
EBS's EV-to-EBITDA is ranked higher than
63% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. EBS: 14.59 )
Ranked among companies with meaningful EV-to-EBITDA only.
EBS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.5  Med: 10.1 Max: 22
Current: 14.59
1.5
22
PEG 5.72
EBS's PEG is ranked lower than
82% of the 95 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. EBS: 5.72 )
Ranked among companies with meaningful PEG only.
EBS' s PEG Range Over the Past 10 Years
Min: 0.82  Med: 4.15 Max: 85.06
Current: 5.72
0.82
85.06
Shiller P/E 31.21
EBS's Shiller P/E is ranked higher than
72% of the 58 Companies
in the Global Biotechnology industry.

( Industry Median: 48.79 vs. EBS: 31.21 )
Ranked among companies with meaningful Shiller P/E only.
EBS' s Shiller P/E Range Over the Past 10 Years
Min: 15.28  Med: 28.09 Max: 40.87
Current: 31.21
15.28
40.87
Current Ratio 4.35
EBS's Current Ratio is ranked higher than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. EBS: 4.35 )
Ranked among companies with meaningful Current Ratio only.
EBS' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 3.98 Max: 5.84
Current: 4.35
1.22
5.84
Quick Ratio 3.62
EBS's Quick Ratio is ranked lower than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. EBS: 3.62 )
Ranked among companies with meaningful Quick Ratio only.
EBS' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 3.54 Max: 5.17
Current: 3.62
0.76
5.17
Days Inventory 199.38
EBS's Days Inventory is ranked lower than
69% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. EBS: 199.38 )
Ranked among companies with meaningful Days Inventory only.
EBS' s Days Inventory Range Over the Past 10 Years
Min: 87.55  Med: 124.71 Max: 311.38
Current: 199.38
87.55
311.38
Days Sales Outstanding 46.33
EBS's Days Sales Outstanding is ranked higher than
64% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. EBS: 46.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
EBS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.39  Med: 68.86 Max: 124.36
Current: 46.33
32.39
124.36
Days Payable 109.21
EBS's Days Payable is ranked higher than
71% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. EBS: 109.21 )
Ranked among companies with meaningful Days Payable only.
EBS' s Days Payable Range Over the Past 10 Years
Min: 109.21  Med: 179.15 Max: 414.03
Current: 109.21
109.21
414.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.20
EBS's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. EBS: -3.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EBS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.3  Med: -4.5 Max: -1.5
Current: -3.2
-13.3
-1.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.72
EBS's Price/Net Current Asset Value is ranked lower than
72% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. EBS: 13.72 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EBS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.39  Med: 6.15 Max: 40.54
Current: 13.72
3.39
40.54
Price/Tangible Book 2.78
EBS's Price/Tangible Book is ranked higher than
74% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. EBS: 2.78 )
Ranked among companies with meaningful Price/Tangible Book only.
EBS' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.83  Med: 1.98 Max: 3.7
Current: 2.78
0.83
3.7
Price/Projected FCF 2.50
EBS's Price/Projected FCF is ranked higher than
64% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. EBS: 2.50 )
Ranked among companies with meaningful Price/Projected FCF only.
EBS' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.06  Med: 1.69 Max: 3.38
Current: 2.5
1.06
3.38
Price/DCF (Earnings Based) 5.40
EBS's Price/DCF (Earnings Based) is ranked lower than
95% of the 20 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. EBS: 5.40 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.26
EBS's Price/Median PS Value is ranked lower than
55% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. EBS: 1.26 )
Ranked among companies with meaningful Price/Median PS Value only.
EBS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.35  Med: 0.98 Max: 1.93
Current: 1.26
0.35
1.93
Price/Peter Lynch Fair Value 3.49
EBS's Price/Peter Lynch Fair Value is ranked lower than
61% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. EBS: 3.49 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
EBS' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.57  Med: 2.57 Max: 7.19
Current: 3.49
0.57
7.19
Price/Graham Number 2.67
EBS's Price/Graham Number is ranked higher than
53% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. EBS: 2.67 )
Ranked among companies with meaningful Price/Graham Number only.
EBS' s Price/Graham Number Range Over the Past 10 Years
Min: 0.48  Med: 1.26 Max: 2.78
Current: 2.67
0.48
2.78
Earnings Yield (Greenblatt) (%) 3.87
EBS's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. EBS: 3.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EBS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.6  Med: 7.3 Max: 59.3
Current: 3.87
2.6
59.3
Forward Rate of Return (Yacktman) (%) 18.33
EBS's Forward Rate of Return (Yacktman) (%) is ranked higher than
55% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. EBS: 18.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
EBS' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -13.5  Med: 2.1 Max: 18.4
Current: 18.33
-13.5
18.4

More Statistics

Revenue (TTM) (Mil) $548.6
EPS (TTM) $ 1.00
Beta1.41
Short Percentage of Float14.68%
52-Week Range $24.47 - 41.91
Shares Outstanding (Mil)40.50

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 495 562
EPS ($) 0.86 1.97
EPS w/o NRI ($) 0.86 1.97
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for EBS

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: Realpage, Anadigics, Emergent BioSolutions, ScanSource Jan 03 2016 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Nov 05 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) Aug 06 2010 
Emergent BioSolutions Inc. (EBS) President & COO Daniel Abdun-nabi sells 18,150 Shares Jul 30 2010 
Weekly CEO Sells Highlight: Yum! Brands Inc, Marchex Inc, iGate Corp, and Emergent BioSolutions Inc. Jul 25 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 18,800 Shares Jul 23 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 130,100 Shares Jul 22 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 84,433 Shares Jul 19 2010 
Emergent BioSolutions Inc. (EBS) CEO and Chairman, 10% Owner Fuad El-hibri sells 52,000 Shares May 14 2010 
Emergent BioSolutions Inc. Reports Operating Results (10-Q) May 06 2010 

More From Other Websites
Should You Get Rid of Emergent BioSolutions (EBS) Now? Dec 09 2016
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 08 2016
Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax... Dec 08 2016
Purcell Julie & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches Of... Dec 07 2016
Erste Group Money Study: Saving against all odds Dec 01 2016
What Hedge Fund Sentiment Says about HudBay Minerals Inc (HBM)? Nov 25 2016
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bearish Manner : EBS-US :... Nov 23 2016
EMERGENT BIOSOLUTIONS INC. Financials Nov 17 2016
Integrated BioTherapeutics, Inc. Announces Licensing Agreement with Emergent BioSolutions for... Nov 15 2016
Emergent BioSolutions, Inc. breached its 50 day moving average in a Bullish Manner : EBS-US :... Nov 11 2016
EMERGENT BIOSOLUTIONS INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
EMERGENT BIOSOLUTIONS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Nov 08 2016
Dr. Kathryn C. Zoon Appointed to Emergent BioSolutions Board of Directors Nov 08 2016
Dr. Kathryn C. Zoon Appointed to Emergent BioSolutions Board of Directors Nov 08 2016
Emergent (EBS) Beats Earnings & Revenue Estimates in Q3 Nov 08 2016
Edited Transcript of EBS earnings conference call or presentation 7-Nov-16 10:00pm GMT Nov 07 2016
Emergent Biosolutions posts 3Q profit Nov 07 2016
Emergent Biosolutions posts 3Q profit Nov 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)